Piedras J, Sánchez-Montero P E, Herrera F M, Córdova M S, Sánchez-Medal L
Research Laboratory, Centro Nacional de la Transfusión Sanguínea, México, D.F.
Arch Med Res. 1993 Spring;24(1):23-6.
The influence of ACD and CPDA-1 anticoagulants, and storage time for 3 and 6 months on F VIII:C activity were compared in cryoprecipitate obtained at -70 degrees C, and -30 degrees C plasma freezing temperature. To eliminate variations in F VIII:C activity between donor plasma, the cryoprecipitation at -70 degrees C and -30 degrees C was made in paired plasma volumes (approximately 100 ml) from each blood unit. Employing ACD plasmas (n = 50), there was no significant difference in F VIII:C activity between cryoprecipitate prepared at -70 degrees C (mean = 31.1 IU/bag) and -30 degrees C (X = 30.5 IU/bag), and the storage did not modify F VIII:C activity. In contrast, in cryoprecipitate prepared from CPDA-1 plasmas (n = 31), the F VIII:C levels obtained at -30 degrees C (mean = 43.8 IU/bg) were significantly higher than those at -70 degrees C (mean = 37.3 IU/bag), but a deterioration of F VIII:C activity (about 50%) was observed after 6 months of cryoprecipitate storage. Therefore, if cryoprecipitate is stored it would be more convenient to use ACD instead of CPDA-1 and make cryoprecipitation either at -70 degrees C or -30 degrees C.
比较了ACD和CPDA - 1抗凝剂以及在-70℃和-30℃血浆冷冻温度下储存3个月和6个月对冷沉淀中F VIII:C活性的影响。为消除供体血浆之间F VIII:C活性的差异，在每个血液单位的配对血浆体积（约100 ml）中分别于-70℃和-30℃进行冷沉淀。使用ACD血浆（n = 50）时，在-70℃（平均= 31.1 IU/袋）和-30℃（X = 30.5 IU/袋）制备的冷沉淀中F VIII:C活性无显著差异，且储存未改变F VIII:C活性。相比之下，在由CPDA - 1血浆制备的冷沉淀（n = 31）中，-30℃时获得的F VIII:C水平（平均= 43.8 IU/bg）显著高于-70℃时（平均= 37.3 IU/袋），但冷沉淀储存6个月后观察到F VIII:C活性下降（约50%）。因此，如果储存冷沉淀，使用ACD而非CPDA - 1并在-70℃或-30℃进行冷沉淀会更方便。
